A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...
Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and will never cause harm. The post New state-of-the-art test identifies ...
A world-first trial of Australian men has confirmed a specialised scan can accurately “light up” prostate cancer, saving ...
Commonwealth Health Wilkes-Barre General Hospital is the first institution in our area to offer the new FDA approved and NCCN-indicated, prostate specific membrane antigen (PSMA) imaging agent to ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Approximately 20% to 40% of men who have surgery for localized prostate cancer will see the cancer return within 10 years, often first detected by a rising PSA blood test. When this happens, doctors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results